 "Cipla to market Serum Institute's paediatric vaccines in Europe")
Cipla Ltd said it has agreed to market paediatric vaccines made by Serum Institute of India Ltd in Europe, in a move that marks India's fourth-largest drugmaker's entry into the vaccines space.
Financial details of the deal with Serum Institute, one of India's largest makers of vaccines, were not disclosed.
Cipla, which exports to over 170 countries, is working on expanding its presence in Europe, a region that contributed 5.7% to the company's total revenue in the year to March 2013.
As part of this strategy, Cipla has launched multiple respiratory products in Europe this year, and launch of some key inhalers is expected in 2015.
"We see vaccines as one of the critical components of our offering to European patients," Cipla's Europe business head Frank Pieters said in a statement.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app